Multi-spectral optoacoustic tomography (MSOT) allows label-free molecular imaging of intrinsic contrast from tissue components, such as lipids, oxyhemoglobin, deoxygenated hemoglobin, H2O, melanin, and collagen simultaneously and in real-time. It enables quantitative monitoring of dynamic processes in the body, such as fat accumulation in the liver or brown fat activation. The temporal resolution brought by MSOT, not only has the potential to serve as an essential element for the assessment of treatment response, but also boosts the discovery and validation of dynamic biomarkers with superior sensitivity and specificity compared to conventional static biomarkers.
In the Biomarkers Group, we study preclinical models of disease with label-free MSOT imaging to develop working pipelines for in vivo detection and quantification of biomarkers, such as lipid content, blood perfusion, and tissue oxygenation. We also explore dynamic biomarkers for disease assessment with or without specific tracers or contrast agents. The scientific output of our group facilitates the study of disease therapies in a preclinical setting and provides an essential base for the translation of optoacoustic biomarkers into the clinic.
The current research topics are:
- Non-alcoholic fatty liver disease diagnosis and monitoring
- Functional imaging of adipose tissues affected by obesity
- Muscle pathology in diabetes